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Abstract
©  2016  American  Association  for  Cancer  Research.Clinical  decision  making  for  human
papillomavirus  (HPV)-negative  head  and  neck  squamous  cell  carcinoma  (HNSCC)  is
predominantly guided by disease stage and anatomic location, with few validated biomarkers.
The epidermal growth factor receptor (EGFR) is an important therapeutic target, but its value in
guiding therapeutic decision making remains ambiguous. We integrated analysis of clinically
annotated tissue microarrays with analysis of data available through the TCGA, to investigate
the idea that expression signatures involving EGFR, proteins regulating EGFR function, and core
cell-cycle modulators might serve as prognostic or drug response-predictive biomarkers. This
work suggests that consideration of the expression of NSDHL and proteins that regulate EGFR
recycling in combination with EGFR provides a useful prognostic biomarker set. In addition,
inactivation  of  the  tumor  suppressor  retinoblastoma  1(RB1),  reflected  by  CCND1/CDK6-
inactivating phosphorylation of RB1 at T356, inversely correlated with expression of EGFR in
patient HNSCC samples. Moreover, stratification of cases with high EGFR by expression levels of
CCND1, CDK6, or  the CCND1/CDK6-regulatory protein p16 (CDKN2A) identified groups with
significant survival differences. To further explore the relationship between EGFR and RB1-
associated cell-cycle activity, we evaluated simultaneous inhibition of RB1 phosphorylation with
the CDK4/6 inhibitor palbociclib and of EGFR activity with lapatinib or afatinib. These drug
combinations had synergistic inhibitory effects on the proliferation of HNSCC cells and strikingly
limited  ERK1/2  phosphorylation  in  contrast  to  either  agent  used  alone.  In  summary,
combinations of CDK and EGFR inhibitors may be particularly useful in EGFR and pT356RB1-
expressing or CCND1/CDK6-overexpressing HPV-negative HNSCC.
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